Know Cancer

forgot password

A Phase 2 Study of Pazopanib (GW786034) in Patients With Advanced and Progressive Malignant Pheochromocytoma or Paraganglioma

Phase 2
18 Years
Open (Enrolling)
Extra-adrenal Paraganglioma, Metastatic Pheochromocytoma, Paraganglioma, Recurrent Pheochromocytoma

Thank you

Trial Information

A Phase 2 Study of Pazopanib (GW786034) in Patients With Advanced and Progressive Malignant Pheochromocytoma or Paraganglioma


I. To assess the anti-tumor activity (in terms of the tumor response rate using the RECIST
criteria) of pazopanib (pazopanib hydrochloride) (GW786034) in patients with advanced
malignant pheochromocytomas and paragangliomas.


I. To assess safety profile of pazopanib. II. To assess duration of tumor response. III. To
assess time to treatment failure. IV. To assess progression-free survival time. V. To assess
overall survival time.


I. To examine the association between baseline CYP isoforms and the maximum pazopanib plasma
level achieved during the first cycle of treatment.

II. To examine whether tumor response is associated with plasma pazopanib levels achieved
during the first cycle of treatment or baseline CYP isoforms.

III. To examine whether severe toxicities leading to pazopanib dose reductions are
associated maximum pazopanib level achieved during the first cycle of treatment or baseline
CYP isoforms.

IV. To examine changes in urinary catecholamine and/or metanephrine levels. V. To examine
whether pazopanib-induced changes in urinary catecholamine and/or metanephrine levels during
the first cycle of treatment may be associated with objective tumor response.

VI. To examine associations between tumor response and somatic mutational status in archived
tumors, or germline mutational status in patient's peripheral blood mononuclear cells,
(presence of SDHD, SDHB, RET, VHL, neurofibromatosis type-1).

VII. To examine associations between tumor response and tumor expression levels of HIF-1a,
VEGF-R (total and phospho-) and microvessel density.

OUTLINE: This is a multicenter study. Patients are stratified according to prior tyrosine
kinase inhibitor (yes vs no). Patients receive pazopanib hydrochloride orally once daily on
days 1-28. Courses repeat every 28 days in the absence of disease progression or
unacceptable toxicity. Patients undergo urine and blood sample collection at baseline and
periodically during study for correlative studies.

After completion of study therapy, patients are followed up every 3-6 months for a maximum
of 3 years.

Inclusion Criteria:

- Histologically or cytologically confirmed unresectable malignant secretory or
non-secretory pheochromocytoma or paraganglioma

- Patients with secretory disease must receive alpha- and beta-adrenergic blockade
for at least 7 days before pazopanib hydrochloride (GW786034) administration

- Objective evidence of tumor progression in the 6-month period prior topazopanib
hydrochloride initiation as assessed by:

- Unequivocal progression of objectively measured disease on successive
appropriate imaging (e.g., CT scan)

- In cases of uncertainty of tumor progression, the Principal Investigator of the
study will be available to assist in decisions

- Measurable disease

- At least one non-nodal lesion whose longest diameter can be accurately measured as >=
2.0 cm with chest x-ray, or as >= 1.0 cm with CT scan, CT component of a PET/CT, or
MRI and/or a lymph node whose short axis must be > 1.5 cm when assessed by CT scan
(CT scan slice thickness recommended to be no greater than 5 mm)

- Note: Tumor lesions in a previously irradiated area are not considered
measurable disease

- Life expectancy > 24 weeks

- ECOG performance status ≤ 2

- Leukocytes >= 3,000/uL

- ANC ≥ 1,500/μL

- Platelet count ≥ 100,000/μL

- Hemoglobin ≥ 9 g/dL (5.6 mmol/L) transfusion not permitted ≤ 7 days of screening

- Total bilirubin ≤ 1.5 times upper limit of normal (ULN) (except in cases of Gilbert
syndrome, where indirect bilirubin may be elevated, but the direct bilirubin remains
within 1.5 times ULN)*

- AST/ALT ≤ 2.5 times ULN*

- Alkaline phosphatase ≤ 2.5 times ULN

- Creatinine ≤ 1.5 mg/dL (133 μmol/L) or normal OR creatinine clearance ≥ 50 mL/min

- Urine protein/creatinine ratio ≤ 1 OR 24-hour urine < 1 gram

- Less than +1 proteinuria (< 30 mg/dL) on 2 consecutive assessments taken ≥ 1
week apart required

- PT/INR/PTT ≤ 1.2 times ULN (unless the patient is receiving coumadin and has stable
INR that is within range for the desired level of coagulation)

- Blood pressure (BP) < 140 mm Hg (systolic) and < 90 mm Hg (diastolic)

- Negative serum pregnancy test

- Not pregnant or nursing

- No men or women of childbearing potential who are unwilling to employ adequate

- Willingness to donate blood and tissue for correlative marker studies

- No history of allergic reactions attributed to compounds of similar chemical or
biologic composition to pazopanib hydrochloride or other agents used in the study

- No QTc prolongation (defined as a QTc interval ≥ 480 msec) or other significant ECG

- No condition (e.g., gastrointestinal tract disease resulting in an inability to take
oral medication or a requirement for IV alimentation, prior surgical procedures
affecting absorption, or active peptic ulcer disease) that impairs their ability to
swallow and retain pazopanib hydrochloride

- None of the following conditions:

- Active peptic ulcer disease

- Known intraluminal bowel metastatic lesions

- Inflammatory bowel disease (e.g., ulcerative colitis, Crohn disease) or other
gastrointestinal conditions which increase the risk of perforation

- History of abdominal fistula, gastrointestinal perforation, or intra-abdominal
abscess ≤ 28 days prior to registration

- Serious or non-healing wound, ulcer, or bone fracture

- None of the following conditions ≤ 6 months from registration:

- Cerebrovascular accident (CVA) or transient ischemic attack (TIA)

- Cardiac arrhythmia

- Admission for unstable angina

- Cardiac angioplasty or stenting

- Coronary artery bypass graft surgery

- Pulmonary embolism, untreated deep venous thrombosis (DVT), or DVT which has
been treated with therapeutic anticoagulation < 6 weeks

- Arterial thrombosis

- Symptomatic peripheral vascular disease

- Class III or IV heart failure as defined by the NYHA functional classification

- A subject who has a history of class II heart failure and is asymptomatic
on treatment may be considered eligible

- No hemoptysis in excess of 2.5 mL (½ teaspoon ) ≤ 8 weeks prior to registration

- No uncontrolled intercurrent illness including, but not limited to, ongoing or active
infection or psychiatric illness/social situations that would limit compliance with
study requirements

- Not requiring heparin other than low-molecular weight heparin

- Recovered from prior therapy

- An unlimited number of prior chemotherapeutic or biologic therapies for this disease

- Prior antiangiogenic therapies (e.g., tyrosine kinase inhibitors) allowed

- More than 4 weeks since prior chemotherapy/systemic therapy (6 weeks for nitrosoureas
or mitomycin C)

- More than 4 weeks since prior radiotherapy

- More than 4 weeks since prior surgery

- No prior pazopanib hydrochloride

- No other concurrent investigational agents

- No concurrent CYP interactive medications such as:

- Strong inhibitors of CYP3A4 such as ketoconazole, itraconazole, clarithromycin,
atazanavir, indinavir, nefazodone, nelfinavir, retonavir, saquinavir,
telithromycin, voriconazole, or grapefruit juice

- Strong inducers of CYP450 such as rifampin

- No concurrent medications that are associated with a risk of QTc prolongation and/or
Torsades de Pointes

- No HIV-positive patients on combination antiretroviral therapy

- Not receiving any medications or substances known to affect or with the potential to
affect the activity or pharmacokinetics of pazopanib

Type of Study:


Study Design:

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

True response proportion in patients who receive the study treatment and have advanced malignant pheochromocytomas and paragangliomas

Outcome Description:

Ninety-five percent confidence intervals for the true response proportion will be calculated according to the approach of Duffy and Santner.

Outcome Time Frame:

Up to 5 years

Safety Issue:


Principal Investigator

Keith Bible

Investigator Role:

Principal Investigator

Investigator Affiliation:

Mayo Clinic


United States: Food and Drug Administration

Study ID:




Start Date:

May 2011

Completion Date:

Related Keywords:

  • Extra-adrenal Paraganglioma
  • Metastatic Pheochromocytoma
  • Paraganglioma
  • Recurrent Pheochromocytoma
  • Paraganglioma
  • Paraganglioma, Extra-Adrenal
  • Pheochromocytoma



Mayo Clinic Rochester, Minnesota  55905
Washington University School of Medicine Saint Louis, Missouri  63110
Metro-Minnesota CCOP St. Louis Park, Minnesota  
M D Anderson Cancer Center Houston, Texas  77030